Can a higher dose slow lung damage in Alpha-1 patients?
NCT ID NCT07326592
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether higher doses of the drug Respreeza/Zemaira can slow lung damage better than the standard dose in adults with emphysema caused by Alpha-1 antitrypsin deficiency. About 270 participants will receive weekly IV infusions for 3 years. The goal is to find the optimal dose to preserve lung function and density.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALPHA1-ANTITRYPSIN DEFICIENCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI model could predict who needs a lung transplant for rare emphysema
- Lung valve aims to release trapped air in severe emphysema
- Surgical fix for failed lung valve treatment shows promise in early trial
- Ultrasound vs. CT: a new way to spot lung damage?
- Gene mutation linked to unexplained emphysema?
- Can a heart drug combo help COPD lungs?